Snyk’s Acquisition of Enso Security

Cooley advised Snyk on the deal. Snyk announced it agreed to acquire Enso Security, pioneers of the industry’s first Application Security Posture Management (ASPM) solution. The...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Structure Therapeutics’ $185.3 Million IPO

Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Chiesi Farmaceutici’s Acquisition of Amryt Pharma Plc

Dechert advised Chiesi Farmaceutici S.p.A. Gide Loyrette Nouel represented BNP Paribas. Amryt Pharma was advised by Cooley. Italian pharmaceutical company Chiesi Farmaceutici has signed a definitive agreement to acquire Amryt Pharma in...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Snyk’s Acquisition of Fugue

Cooley advised Snyk on the deal. Snyk, a leader in developer security, announced its acquisition of Fugue, a cloud security and compliance company. This milestone marks Snyk’s...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Exscientia’s $510.4 Million IPO

Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here